Paraoxonase-1 (PON-1) Arylesterase Activity Levels in Patients with Coronary Artery Disease: A Meta-Analysis. (10th March 2022)

• Record Type: Journal Article
• Authors: Zuin, Marco; Trentini, Alessandro; Marsillach, Judit; D'Amuri, Andrea; Bosi, Cristina; Roncon, Loris; Passaro, Angelina; Zuliani, Giovanni; Mackness, Mike; Cervellati, Carlo
• Other Names: Pichini Simona Academic Editor.
• Is Part Of: Disease markers. Volume 2022(2022)
• Publication Date: 2022-03-10
• Subjects: Diagnosis -- Periodicals; Biochemical markers -- Periodicals; Pathology -- Periodicals; 616
• DOI: 10.1155/2022/4264314
• Languages: English
• ISSNs: 0278-0240

Abstract

Abstract : Aim . To review and compare the PON-1 arylesterase activity between coronary artery disease (CAD) and non-CAD patients. Methods . Data were obtained by searching MEDLINE and Scopus for all investigations published between January 1, 2000 and March 1, 2021 comparing PON-1 arylesterase activity between CAD and controls. Results . Twenty studies, based on 5417 patients, met the inclusion criteria and were included in the analysis. A random effect model revealed that PON-1 arylesterase activity was significantly lower in the CAD group compared to controls (SMD = – 0.587, 95 % CI = − 0.776 to -0.339, p < 0.0001, I 2 = 92.3 % ). In CAD patients, the PON-1 arylesterase activity was significantly higher among CAD patients without diabetes mellitus (DM) compared to those with diabetes (SMD: 0.235, 95% CI: 0.014 to 0.456, p = 0.03, I 2 = 0 % ). Conclusions . PON-1 activity is significantly lower in CAD patients, and those without DM presented a significantly higher PON-1 arylesterase activity.